MedTrace Logo

ESBA1008 Microvolume Study

NCT01849692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2016-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).

Conditions

  • Exudative Age-Related Macular Degeneration

Interventions

DRUG

ESBA1008 solution

Intravitreal injection or infusion

DRUG

Ranibizumab

Intravitreal injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Project Group Leader, GCRA, Pharma · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01849692 on ClinicalTrials.gov